Loading
Life sciences · Journal article
Clinical Cancer Bulletin · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. More than 80% of patients are diagnosed at an advanced stage, and the 5‑year survival rate remains approximately 13% [ 1, 2 ]. For patients with metastatic PDAC (mPDAC), first-line chemotherapy yields a median overall survival (OS) of less than one year [ 3, 4 ]. The situation in the second‑line setting is even more discouraging: objective response rates (ORRs) are usually below 10%, median progression‑free survival (PFS) is only 2–3 months, and median OS ranges from 5 to 7 months [ 5 ]. Over the past two decades, more than 20 second‑line clinical trials have been conducted, but nearly all of them have failed. Given the long-standing therapeutic stagnation in this field, the simultaneous publication of two daraxonrasib studies in N Engl J Med marks a historic turning point [ 6, 7 ].